Earnings ·
Tactile Systems reports Q3 revenue of $91.9M and raises full-year Adjusted EBITDA guidance to $50M-$52M
TCMDTactile Systems Technology Inc
Tactile Systems Technology reported third-quarter 2026 total revenue of $91.9 million, a 7% increase year-over-year, driven by a 13% rise in its lymphedema product line to $81.8 million. Net income decreased to $7.2 million ($0.31 diluted EPS) from $8.2 million in the prior-year quarter as operating expenses rose 13%. The company raised its full-year 2026 Adjusted EBITDA guidance to a range of $50 million to $52 million, up from the previous expectation of $49 million to $51 million, while maintaining revenue growth expectations. Additionally, Tactile repurchased $6.2 million of stock during the quarter and received FDA clearance for an expanded indication for its LymphaTech 3D Scanner. The company operates in the medical technology sector, developing and marketing at-home therapies for chronic conditions such as lymphedema and respiratory disorders.